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The Scandinavian Starch for Severe Sepsis / Septic Shock (6S) trial showed that hydroxyethyl starch was harmful
compared to Ringer’s acetate in patients with severe sepsis when used according to clinical practice and in
alignment with the recommendations by the manufactures and authorities. The different interpretation by Chapell
and Jacob’s rely on misreading of the trial publication and is not supported by the trial data. Several hypotheses
may be made regarding less harmful ways of using HES in critically ill patients, but clinicians, guideline committee
members and authorities need to acknowledge that such safer ways have not yet been identified.
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In a recent commentary in the Scandinavian Journal of
Trauma, Resuscitation and Emergency Medicine Chappell
and Jacob provide their view of the three largest,
randomised clinical trials of hydroxyethyl starch in crit-
ically ill patients [1]. The authors’ interpretation of
these trials and their view of the safety with HES are
far from those of independent authors conducting
high-quality systematic reviews [2-7], the US Food and
Drug Administration [8] and the European Medicines
Agency’s Pharmacovigilance Risk Assessment Commit-
tee [9].
Unfortunately, several claims regarding the Scandinavian
Starch for Severe Sepsis/Septic Shock (6S) trial rely on
misreading of the main publication of this trial [10] and
are not supported by the trial data.
The 6S trial aimed at testing the effect of HES versus
Ringer’s acetate as used in clinical practice in a high
number of different intensive care units. The 24 hour
window from diagnosis of severe sepsis resembles clinical
practice, where fluid resuscitation in septic patients is
initiated without waiting for the results of new blood
samples to confirm the diagnosis of severe sepsis.
Forty-nine percent, not 60%, received colloids in the
24 hours prior to randomisation, but the clinician judged
that fluid resuscitation was still needed as this was an* Correspondence: anders.perner@rh.regionh.dk
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reproduction in any medium, provided the orinclusion criterion. Such judgement is complex, but may
have been based on poor peripheral perfusion, oliguria,
increased vasopressor need etc. Thus, the claim that the
patients were hemodynamically stabilized at randomisation
is unjustified. Also, CVP and ScvO2 were only registered
in a minority of patients and either value may have
been abnormal or considered abnormal in combination
with other parameters by the clinicians assessing these
patients. Neither we nor Chappell and Jacob can know
how individual clinicians judged patients.
Most trial fluid was given in the first 38 hours (day 1
lasted median 14 hours) and the cumulative total dose
of HES was less than the labelled maximum daily dose
of HES (Table 1). Thus, the statement that HES was
given in high amounts and over a prolonged period of
time is not true for the majority of patients.
During the trial, 38 of 400 patients (10%) in the Ringer’s
group received synthetic colloid (almost exclusively HES).
Sixty-five patients (16%) in the Ringer’s group received
albumin for other indications than volume expansion.
Overall, 92 (23%) patients in the Ringer’s group received
a colloid during the trial, and not 32% as stated by
Chappell and Jacob. As the use of albumin was similar in
both intervention groups, this unlikely affected the trial
results.
Most patients discontinued trial fluid due to severe
bleeding or renal replacement therapy (RRT) as stipulated
in the protocol [11]. To exclude these patients from the
primary analysis would mask the harmful side effects oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Doses of trial fluid
HES 130/0.42 (N = 398) Ringer’s acetate (N = 400)
Volume median (IQR) Volume median (IQR) P Value
Trial Fluid, ml
Day 1 1500 (1000–1500) 1500 (1000–1550)
Day 2 1000 (300–1500) 1000 (500–1500)
Day 3 500 (0–1000) 425 (0–1000)
Day 4 0 (0–500) 0 (0–500)
Day 5 0 (0–500) 0 (0–500)
Cumulative Dose (day 1–89)
In ml 3000 (1500–5000) 3000 (1800–5500) 0.20
In ml/kg 44 (24–75) 47 (25–76) 0.18
The table show volume of trial fluid according to intervention group and days after randomisation. The presentation differs from that of the primary publication
of the 6S trial, but reflects exactly the same data.
The P value is from Wilcoxon rank-sum test comparing the total trial fluid volume in all patients. IQR denotes interquartile range.
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who discontinued trial fluid for other reasons, showed
comparable estimates of increased risk of death supporting
the primary results.
Kidney failure without RRT was not a ‘clear’ or ‘abso-
lute’ contraindication for HES according to the steering
committee and scientific advisors of the trial, B Braun
Melsungen AG and the Medicines Agencies in Denmark,
Norway, Finland and Iceland, who all approved the proto-
col and the inclusion of these patients. It is important
to note that the increased risk of death with HES was
independent of kidney failure at inclusion in the pre-
planned subgroup analysis [10].
Data on mechanical ventilation and hospital length of
stay can be found in the main publication of the 6S trial
as days alive without ventilation and days alive and out
of hospital, respectively. We find these endpoints more
valid as they are less affected by survival bias.
Taken together, the 6S trial showed that HES was
harmful compared to Ringer’s acetate in patients with
severe sepsis when used according to clinical practice
and in alignment with the recommendations by the
manufactures and authorities. Several hypotheses may
be made regarding less harmful ways of using HES in
critically ill patients, but clinicians, guideline committee
members and authorities need to acknowledge that such
safer ways have not yet been identified.
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